Home
Conditions
Blood Protein Disorders

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,037 public trials 564 recruiting studies

Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Active, Not Recruiting

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

NCT03104842

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Vivantes Am Urban Berlin, Germany

Campus Benjamin Franklin Charite Berlin Berlin, Germany

Vivantes Klinikum Neukölln Berlin, Germany

Städt. Kliniken Bielefeld Klinikum Mitte Bielefeld, Germany

View all 17 locations

View Trial Details

Active, Not Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

NCT05646836

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Royal Adelaide Hospital Adelaide, South Australia, Australia

Peter Maccallum Cancer Centre Melbourne, Victoria, Australia

Alfred Hospital Melbourne, Victoria, Australia

Sygehus Lillebaelt - Vejle Sygehus Vejle, Denmark

View all 13 locations

View Trial Details

Active, Not Recruiting

Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma

NCT06073353

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

NCT05002816

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Yale New Haven Hospital New Haven, Connecticut, United States

View Trial Details

Active, Not Recruiting

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

NCT05981209

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

NCT05514990

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Los Angeles County-USC Medical Center Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Active, Not Recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +31 more
Locations: University of Arizona Cancer Center - Tucson /ID# 210548 Tucson, Arizona, United States

UCLA Santa Monica Hematology Oncology /ID# 210551 Los Angeles, California, United States

Ingalls Memorial Hosp /ID# 210553 Harvey, Illinois, United States

Dana-Farber Cancer Institute /ID# 215360 Boston, Massachusetts, United States

View all 56 locations

View Trial Details

Active, Not Recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, Not Recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

NCT06385496

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Blood Protein Disorders

Blood Protein Disorders trial results

Related conditions